Adjunctive Statin Therapy on Cholesterol and Clinical Symptoms in Schizophrenia Treated with Risperidone

Penulis

  • Irma Santy Department of Psychiatry, Faculty of Medicine, University of Hasanuddin, Makassar, Indonesia
  • Andi Ummulkhair Pawallangi Irawan Psychiatry Specialist Program, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
  • Erlyn Limoa Department Psychiatry, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
  • Fanny Wijaya Department Psychiatry, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
  • Ilma Khaerina Amaliyah Bakhtiar Department of Psychiatry, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia
  • Muhammad Alim Jaya Department of Psychiatry, Faculty of Medicine, Universitas Muslim Indonesia, Makassar, Indonesia

DOI:

https://doi.org/10.33096/7y6f9607

Kata Kunci:

Schizophrenia, risperdone, statin, cholesterol, PANSS

Abstrak

Background: Schizophrenia is associated with the metabolic side effects of atypical antipsychotics, such as hypercholesterolemia.

Objective: To evaluate the effect of adjuvant statin therapy on total cholesterol levels and clinical symptoms in patients with schizophrenia treated with risperidone.

Methods: This randomized clinical trial was conducted on 36 patients with schizophrenia at RSKD Dadi, South Sulawesi. The subjects were randomized into risperidone-only and risperidone plus statin groups.

Results: Statin adjuvant therapy reduced total cholesterol levels and improved clinical symptoms (PANSS scores) compared to the control group.

Conclusion: Adjuvant statin therapy is potentially beneficial in reducing cholesterol levels and improving clinical outcomes in patients with schizophrenia receiving risperidone.

Unduhan

Diterbitkan

2025-12-22

Terbitan

Vol 10 No 2 (2025): UMI Medical Journal (Issue in Progress)

Bagian

Original Article